Andrew J Lawrence

Title: Andrew J. Lawrence: Innovator in Relaxin Polypeptides

Introduction: Andrew J. Lawrence, located in Parkville, Australia, is a notable inventor in the field of biochemistry, particularly known for his work on single chain relaxin polypeptides. His research contributes significantly to our understanding of these biochemicals and their implications in medical science.

Latest Patents: Lawrence holds a patent for "Single chain relaxin polypeptides," which focuses on biologically active single chain relaxin polypeptides that feature a relaxin B chain derived from relaxin-3. This invention includes polypeptides that are truncated by one or more amino acids at the C-terminus of the relaxin-3 B chain. These single chain relaxin polypeptides act as antagonists of the RXFP3 receptor, with certain embodiments being selective antagonists, indicating their potential therapeutic applications.

Career Highlights: Throughout his career, Andrew J. Lawrence has amassed valuable experience working with esteemed institutions. Notably, he has contributed to research at The University of Queensland and the Howard Florey Institute of Experimental Physiology and Medicine, enhancing his expertise in physiological and medicinal research.

Collaborations: Lawrence has collaborated with several renowned professionals, including Karl Johan Rosengren and Linda Maria Haugaard-Kedstrom. These collaborations have likely enriched his research and contributed to the advancement of knowledge in the field.

Conclusion: Andrew J. Lawrence is a significant figure in the realm of biochemistry and pharmacology, with a focused innovation on single chain relaxin polypeptides. His work lays the foundation for future developments in receptor antagonism and its applications in medicine, highlighting the importance of his contributions to science and innovation.